Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06207799 · ClinicalTrials.gov registry record · Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

A Phase 2 study of Multiple Myeloma and Post-transplant MRD-guided Maintenance Therapy, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06207799 is a Phase 2 study of Multiple Myeloma and Post-transplant MRD-guided Maintenance Therapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06207799, a Phase 2 study of Multiple Myeloma and Post-transplant MRD-guided Maintenance Therapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

Conditions Studied

Multiple Myeloma Post-transplant MRD-guided Maintenance Therapy Pre-transplant Purging

Interventions

  • DRUG Melphalan
  • DRUG Busulfan
  • DRUG Lenalidomide
  • DRUG Elranatamab
  • DRUG Plerixafor

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-17
Est. Completion 2031-12-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06207799

The ClinicalTrials.gov registry entry for NCT06207799 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.

NCT06207799 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06207799 about?

NCT06207799 is a clinical study titled "Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma". To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

What is the current status of trial NCT06207799?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-07-17. Estimated completion is 2031-12-31.

What conditions does trial NCT06207799 study?

This clinical trial studies the following conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging.

What interventions are being tested in trial NCT06207799?

The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Lenalidomide (DRUG), Elranatamab (DRUG), Plerixafor (DRUG).

Who is sponsoring clinical trial NCT06207799?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06207799 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Post-transplant MRD-guided Maintenance Therapy

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.